PaxMedica
- Company typePublic
- Founded2018
- HeadquartersTarrytown, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
PaxMedica firmographics
Firmographics- Name
- PaxMedica
- Website
- https://paxmedica.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
PaxMedica industry classification
Industry- Product category
- Clinical-stage biopharmaceutical drug development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where PaxMedica is headquartered
LocationHeadquarters
- HQ city
- Tarrytown
- HQ country
- United States
- HQ region
- North America
Markets served
PaxMedica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
PaxMedica product offering
Product offeringCore offering
PaxMedica is a clinical-stage biopharmaceutical company developing drug therapies for neurodevelopmental and neurological disorders, with its primary drug candidate PAX-101 being advanced through clinical development. The company is pursuing manufacturing validation and NDA submission for PAX-101 to treat autism spectrum disorder (ASD) and other neurological conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- PAX-101
Companies that use PaxMedica
Customer profileSegments1 record
Ideal customer profiles1 record
PaxMedica technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
PaxMedica partnerships and signals
Strategic signalScale indicators3 records
PaxMedica competitors and assessment
Company assessmentDirect peers
- Axsome Therapeutics: CNS-focused biopharmaceutical company developing and commercializing therapies for neurological and psychiatric conditions; comparable in therapeutic focus and stage of CNS drug development to PaxMedica.
- Zynerba Pharmaceuticals: Clinical-stage biopharmaceutical company developing cannabinoid-based transdermal therapies for Fragile X syndrome and autism spectrum disorder—a near-direct comparator to PaxMedica's PAX-101 in neurodevelopmental disorders.
- Marinus Pharmaceuticals: Clinical-stage biopharmaceutical company developing therapeutics for seizure disorders and other neurological conditions; comparable as a small-cap CNS drug developer at similar stage.
- Karuna Therapeutics: CNS-focused biopharmaceutical company developing therapies for neuropsychiatric conditions; comparable as a clinical-to-commercial-stage CNS innovator pharma.
- Sage Therapeutics: Biopharmaceutical company developing CNS therapies for disorders including epilepsy and depression; directly comparable as a small-to-mid cap CNS-focused innovator pharma.
- Taysha Gene Therapies: Clinical-stage gene therapy company focused on monogenic CNS diseases; comparable as a small-cap neurology-focused biotech pursuing rare neurodevelopmental indications.
Broad incumbents
- Acadia Pharmaceuticals: Established biopharmaceutical company commercializing CNS therapies (e.g., Rett syndrome, Parkinson's psychosis); comparable CNS/neuro focus but with commercial-stage assets.
- Ionis Pharmaceuticals: Established RNA-targeted therapeutics company with a significant neurological disease pipeline; comparable CNS/neurodegenerative development focus.
- Denali Therapeutics: Biopharmaceutical company developing therapeutics for neurodegenerative diseases; comparable CNS/neurodegenerative focus though at a larger scale and broader modality footprint.
- BioMarin Pharmaceutical: Established biopharmaceutical company developing treatments for rare diseases including neurological conditions; comparable neuro/rare-disease focus but at commercial scale.
Market position
Customer concentration
PaxMedica financial estimates
Financial estimateRevenue estimate
Valuation estimate
PaxMedica leadership team
Management profileNumber of profiles
Profiles2 records
PaxMedica funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PaxMedica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PaxMedica
What does PaxMedica do?
PaxMedica is a clinical-stage biopharmaceutical company developing drug therapies for neurodevelopmental and neurological disorders, with its primary drug candidate PAX-101 being advanced through clinical development. The company is pursuing manufacturing validation and NDA submission for PAX-101 to treat autism spectrum disorder (ASD) and other neurological conditions.
Is PaxMedica a public or private company?
PaxMedica is a public company. It is classified as public and is currently operating.
When was PaxMedica founded?
PaxMedica was founded in 2018. It employs 1 to 10 people.
Where is PaxMedica based?
PaxMedica is headquartered in Tarrytown, United States, in the North America region.
Who are PaxMedica's main competitors?
Direct peers on record are Axsome Therapeutics, Zynerba Pharmaceuticals, Marinus Pharmaceuticals, Karuna Therapeutics, Sage Therapeutics and Taysha Gene Therapies. Broad incumbents are Acadia Pharmaceuticals, Ionis Pharmaceuticals, Denali Therapeutics and BioMarin Pharmaceutical.
Does PaxMedica have an API?
No public API is recorded for PaxMedica.
What industry is PaxMedica in?
PaxMedica's product category is Clinical-stage biopharmaceutical drug development. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.